Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

This study has been completed.

First Received on September 6, 2002. Last Updated on December 20, 2007 History of Changes

Sponsor:	Amgen
Information provided by:	Amgen
ClinicalTrials.gov Identifier:	NCT00044902

Purpose

Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent or in combination with chemotherapy as their last treatment and who demonstrated a partial response or complete response for at least 12 months.

Condition	Intervention	Phase
Non-Hodgkin's Lymphoma	Drug: epratuzumab	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Lymphoma

Drug Information available for: Epratuzumab Yttrium Y 90 Epratuzumab Yttrium Y 90 Epratuzumab Tetraxetan

U.S. FDA Resources

Further study details as provided by Amgen:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL * Received and failed at least 1 prior regimen of chemotherapy * Rituximab-naive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at least 12 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00044902

Sponsors and Collaborators

Amgen

Investigators

Study Director:

Amgen

More Information

Additional Information:

AmgenTrials clinical trials website This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Global Development Leader, Amgen Inc.
ClinicalTrials.gov Identifier:	NCT00044902 History of Changes
Obsolete Identifiers:	NCT00054379
Other Study ID Numbers:	20010138
Study First Received:	September 6, 2002
Last Updated:	December 20, 2007
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms

Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on February 12, 2012